España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Comments
Close menu
Loading...
Otsuka Holdings
OTSKY
OTCPK
Watchlist
Leave a Comment
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$23.73
0.58
2.51%
At Close: -
15 minutes delayed
Get Report
Comment
Otsuka Holdings (OTSKY) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Otsuka Holdings (OTC:OTSKY) Stock
Otsuka Holdings Stock (OTC: OTSKY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, April 16, 2024
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
Vandana Singh
Wednesday, March 20, 2024
Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
Vandana Singh
Monday, September 18, 2023
One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
Faith Ashmore
-
Sponsored
Thursday, August 24, 2023
Regulatory Setback For Medtronic's High Blood Pressure Device - FDA Backed Japanese Firms' Similar Device For Uncontrolled Hypertension
Vandana Singh
Wednesday, August 23, 2023
Individuals With Uncontrolled Hypertension - FDA Adcomm Panel Just Supported Japanese MedTech's Blood Pressure Treatment Device
Vandana Singh
Thursday, May 11, 2023
FDA Approves First Drug To Treat Agitation Symptoms Associated With Dementia Due To Alzheimer's Disease
Happy Mohamed
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation
Vandana Singh
Thursday, November 03, 2022
Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches
Nick Thomas
-
Sponsored
Wednesday, August 17, 2022
This Upstart Supplement Company Says It's Making Huge Strides In Selling Its Well-Told Story
Mark Gilman
-
Sponsored
Friday, August 05, 2022
Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study
Vandana Singh
Friday, July 01, 2022
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Vandana Singh
Monday, May 16, 2022
Why Are Akebia Therapeutics Shares Falling Today?
Vandana Singh
Wednesday, March 30, 2022
FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia
Vandana Singh
Tuesday, June 01, 2021
Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia
Vandana Singh
Friday, January 15, 2021
Novavax Hires Regulatory Expert As Coronavirus Vaccine Inches Closer To Emergency Use Filing
Shanthi Rexaline
Wednesday, November 25, 2020
JD.com Unit Set For Asia's Largest-Ever Healthcare IPO Above $3B
Aditya Raghunath
Friday, August 07, 2020
Earnings Scheduled For August 7, 2020
Benzinga Insights
Tuesday, March 24, 2020
Stocks That Hit 52-Week Highs On Tuesday
Benzinga Insights
Friday, January 10, 2020
Stocks That Hit 52-Week Highs On Friday
Lisa Levin
Monday, December 23, 2019
Stocks That Hit 52-Week Highs On Monday
Lisa Levin
Friday, December 20, 2019
Stocks That Hit 52-Week Highs On Friday
Lisa Levin
Thursday, August 24, 2017
Otsuka, Mylan Announce License Agreement to Commercialize Delamanid for MDR-TB in High-Burden Countries
Benzinga
Thursday, April 27, 2017
4 Things To Know About Akebia's New Vadadustat Collaboration With Otsuka Pharma
Benzinga
Sunday, December 07, 2014
FDA Approves Labeling Update of Abilify Maintena for Extended-Release Injectable Suspension
Benzinga
Tuesday, December 02, 2014
Benzinga's M&A Chatter for Tuesday December 2, 2014
Benzinga
UPDATE: Otsuka to Acquire Avanir for $17.00/S...
Benzinga
Avanir Pharmaceuticals to be Acquired by Otsuka Pharmaceutical for $3.5B
Benzinga
Monday, October 07, 2013
Astex Pharmaceuticals Announces Expiration of HSR Waiting Period for Otsuka Tender Offer
Benzinga
Friday, April 12, 2013
Otsuka's NDA for Tolvaptan for Autosomal Dominant Polycystic Kidney Disease , Accepted for Review by FDA
Benzinga
